Ionis Pharmaceuticals Files 8-K
Ticker: IONS · Form: 8-K · Filed: Dec 20, 2024 · CIK: 874015
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
IONIS filed an 8-K on 12/20 for an event on 12/19 - details pending.
AI Summary
Ionis Pharmaceuticals, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 19, 2024. The filing is related to "Other Events" and "Financial Statements and Exhibits." No specific financial details or material events were disclosed in the provided text.
Why It Matters
This filing indicates a regulatory update from Ionis Pharmaceuticals, Inc., which could contain important information for investors regarding company events or financial disclosures.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate disclosure of significant negative news.
Key Players & Entities
- IONIS PHARMACEUTICALS INC (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
- December 20, 2024 (date) — Date of report
- 2855 Gazelle Court Carlsbad, CA 92010 (address) — Principal Executive Offices
- ISIS PHARMACEUTICALS INC (company) — Former company name
FAQ
What specific event triggered this 8-K filing on December 19, 2024?
The provided text does not specify the exact event, only that it falls under 'Other Events' and 'Financial Statements and Exhibits'.
What is the primary business of Ionis Pharmaceuticals, Inc. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
When did Ionis Pharmaceuticals, Inc. change its name from ISIS PHARMACEUTICALS INC?
The date of the name change was March 28, 1993.
What is the state of incorporation for Ionis Pharmaceuticals, Inc.?
The state of incorporation is Delaware.
What is the principal executive office address for Ionis Pharmaceuticals, Inc.?
The address is 2855 Gazelle Court, Carlsbad, CA 92010.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 10 · Accepted 2024-12-20 14:28:21
Filing Documents
- ef20040455_8k.htm (8-K) — 27KB
- ef20040455_ex99-1.htm (EX-99.1) — 25KB
- image00001.jpg (GRAPHIC) — 2KB
- 0001140361-24-050057.txt ( ) — 195KB
- ions-20241219.xsd (EX-101.SCH) — 4KB
- ions-20241219_lab.xml (EX-101.LAB) — 21KB
- ions-20241219_pre.xml (EX-101.PRE) — 16KB
- ef20040455_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On December 19, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: December 20, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel